Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial-Reference-Cited by-同舟云学术

Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

Published:2019-01-18 Issue:1 Volume:14 Page:
ISSN:1862-3522
Container-title:Archives of Osteoporosis
language:en
Short-container-title:Arch Osteoporos

Author:

Minisola Salvatore,Marin Fernando,Kendler David L.,Geusens Piet,Zerbini Cristiano A. F.,Russo Luis A.,Casado Enrique,Fahrleitner-Pammer Astrid,Stepan Jan J.,Lespessailles Eric,Moericke Rüdiger,Bagur Alicia,Lakatos Péter,López-Romero Pedro,Body Jean Jacques

Publisher

Springer Science and Business Media LLC

Subject

Orthopedics and Sports Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11657-019-0561-x.pdf

Reference20 articles.

1. Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P (2018) Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240. https://doi.org/10.1016/S0140-6736(17)32137-2

2. Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CAF, Minisola S, Body JJ, Lespessailles E, Greenspan SL, Bagur A, Stepan JJ, Lakatos P, Casado E, Moericke R, López-Romero P, Fahrleitner-Pammer A (2018) Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial. J Bone Miner Res 33(5):783–794. https://doi.org/10.1002/jbmr.3384

3. Dawson-Hughes B, Chen P, Krege JH (2007) Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 92(12):4630–4636. https://doi.org/10.1210/jc.2007-0239

4. Cosman F, Dawson-Hughes B, Wan X, Krege JH (2012) Changes in vitamin D metabolites during teriparatide treatment. Bone 50(6):1368–1371. https://doi.org/10.1016/j.bone.2012.02.635

5. Mok J, Brown C, Moore AEB, Min SS, Hampson G (2018) Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status. Endocr Res 13:1–8. https://doi.org/10.1080/07435800.2018.1454461

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis;Frontiers in Endocrinology;2024-09-02

2. Influencia del calcio y colecalciferol en el tratamiento de la osteoporosis;Medicina Clínica Práctica;2024-04

3. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials;BMJ;2023-05-02

4. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians;Annals of Internal Medicine;2023-02

5. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women;Cochrane Database of Systematic Reviews;2022-05-03